Jockeying for position

WASHINGTON - The 105th Congress will not adjourn for another week, but strategies for political battles that will affect the biotech industry in the 106th Congress are already being plotted.

Legislation was introduced last week addressing two areas that are likely to be on the congressional agenda early next year: capital gains incentives and Medicare drug price controls...